Skip to main content
Quest Diagnostics

Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy

Clinicopathologic Spectrum of Lysozyme-Associated Nephropathy

Authors: Kudose S, Cossey LN, Canetta PA, Sekulic M, Vanbeek CA, Huls FB, Gupta I, Bu L, Alexander MP, Cornell LD, Fidler ME, Markowitz GS, Larsen CP, D’Agati V, Nasr SH, Santoriello D.

Citation: Kidney Int Rep. Published online May 15, 2023. doi: 10.1016/j.ekir.2023.05.007

Specialties: Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath, a subsidiary of Quest Diagnostics.

Related content

On-Demand Webinar
Hemepath Master Class: Chronic lymphocytic leukemia CLL small lymphocytic lymphoma SLL
Validation and adoption of an IGVH mutational status assay in chronic lymphocytic leukemia (CLL) using next-generation sequencing (NGS) in a clinical laboratory
Publication
Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation
Test FAQ
Kidney Profile
Test FAQ
Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping
Test FAQ
CKD-EPI Creatinine Equation (2021) for Creatinine-based eGFR

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.